RenovoRx price target lowered to $7 from $13 at Roth MKM

Roth MKM lowered the firm’s price target on RenovoRx to $7 from $13 but keeps a Buy rating on the shares. The company’s Q3 results were in line with expectations though the key update for the quarter was that enrollment timelines pushed back slightly with second interim analysis targeted for late 2024 and that the launch is now targeted for 2027 from 2026, the analyst tells investors in a research note.